Siddharth Padia, MD, discusses the utility of TheraSphere™ Yttrium-90 Glass Microspheres in patients with hepatocellular carcinoma.
Siddharth Padia, MD
Advertisement
Articles by Siddharth Padia, MD
Siddharth Padia, MD, discusses the data that led to the March 2021 FDA approval of TheraSphere™ Yttrium-90 Glass Microspheres for use in patients with hepatocellular carcinoma.
Advertisement
Latest Updated Articles
Dr. Padia on the Utility of Y-90 Glass Microspheres in HCCPublished: June 5th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5